elexacaftor (Trifakta) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA
AACT

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: Cc1nn(C)cc1S(=O)(=O)NC(=O)c1ccc(-n2ccc(OCC(C)(C)C(F)(F)F)n2)nc1N1C[C@@H](C)CC1(C)C
  • InChIKey: MVRHVFSOIWFBTE-INIZCTEOSA-N
  • Mol. Mass: 597.66
  • ALogP: 4.02
  • ChEMBL Molecule:
    elexacaftor  
More Chemistry

Pharmacology

Combination drugs

( ivacaftor (Kalydeco), tezacaftor (Trifakta), elexacaftor (Trifakta) - other names: elexacaftor/tezacaftor/ivacaftor, kaftrio )

Alternative names

vx-445

Organizations (14)

Research & Development (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (1)


 

Cystic Fibrosis (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Cystic Fibrosis (Phase 4)

Drug Interactions (Phase 4)

Medication Adherence (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 25
  • # of Trial Organizations: 13

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue